DUBLIN, Ireland, Sept. 11, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Irina Konstantinovsky executive vice president, chief human resources officer, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately.
“Irina is an accomplished human resources professional with an excellent track record of attracting, developing and retaining talent as well as building an inclusive and engaging culture,” said Walbert. “Her extensive experience will be critical as the company continues to grow and evolve.”
Prior to Horizon, Konstantinovsky was vice president of global talent at Baxter International Inc. where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide.
“Horizon Pharma has a strong, patient-centered culture with passionate, committed employees at its core,” said Konstantinovsky. “I’m looking forward to helping build a world-class human resources function that continues to foster and develop these strengths.”
Prior to Baxter, Konstantinovsky spent 15 years in senior partner and director roles at Towers Watson (currently Willis Towers Watson), a global human resources consulting firm serving Fortune 1000 companies. While in these roles, she served as the interim chief human resource officer at Capital BlueCross for two years.
She has a Bachelor of Arts in Education from the University of Buenos Aires and master’s degrees in higher education and industrial and labor relations from Cornell University. In addition, Konstantinovsky serves on the board of the Human Resource Management Association of Chicago.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]


Italy Fines Apple €98.6 Million Over App Store Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Approves Mitapivat for Anemia in Thalassemia Patients
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 



